Schrodinger (NASDAQ:SDGR – Get Free Report) and Health Catalyst (NASDAQ:HCAT – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Schrodinger and Health Catalyst, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Schrodinger | 1 | 3 | 4 | 0 | 2.38 |
| Health Catalyst | 1 | 5 | 0 | 0 | 1.83 |
Schrodinger currently has a consensus target price of $26.67, indicating a potential downside of 5.19%. Health Catalyst has a consensus target price of $2.01, indicating a potential upside of 43.97%. Given Health Catalyst’s higher probable upside, analysts plainly believe Health Catalyst is more favorable than Schrodinger.
Valuation & Earnings
This table compares Schrodinger and Health Catalyst”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Schrodinger | $269.20 million | 7.71 | -$103.26 million | ($0.79) | -35.60 |
| Health Catalyst | $272.20 million | 0.39 | -$177.97 million | ($2.83) | -0.49 |
Schrodinger has higher earnings, but lower revenue than Health Catalyst. Schrodinger is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Schrodinger and Health Catalyst’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Schrodinger | -22.02% | -18.12% | -9.07% |
| Health Catalyst | -74.24% | -4.84% | -2.02% |
Volatility & Risk
Schrodinger has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Health Catalyst has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.
Institutional & Insider Ownership
79.1% of Schrodinger shares are held by institutional investors. Comparatively, 85.0% of Health Catalyst shares are held by institutional investors. 10.1% of Schrodinger shares are held by insiders. Comparatively, 19.4% of Health Catalyst shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
About Schrodinger
Schrödinger, Inc. develops computational software used to support drug discovery and materials research. Its platform applies physics-based modeling, computational chemistry and machine learning to help researchers analyze molecular properties and identify promising candidates. The company’s tools are used by pharmaceutical and biotechnology companies, academic institutions and other research organizations. Alongside software sales and subscriptions, Schrödinger works with partners on drug discovery programs and advances a portfolio of its own therapeutic candidates.
About Health Catalyst
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its solutions are designed to help providers use clinical, operational, and financial data to support decision-making and improve care delivery. The company’s offerings include a data platform that brings together information from multiple sources, analytics applications for healthcare workflows, and professional services. These services can include implementation, data management, and support for organizations developing and applying analytics programs.
Receive News & Ratings for Schrodinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrodinger and related companies with MarketBeat.com's FREE daily email newsletter.
